TATA-box binding protein associated factor, RNA polymerase I subunit AGenealiases: MGC:17061 · RAFI48 · SL1 · TAFI48
Q-omics provides the consensus-scored TAF1A profile across patient tissues and cancer cell-line models. TAF1A expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, TAF1A is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, TAF1A RNA expression shows 20,142 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, HNSC, and ACC as cancer lineages where TAF1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF1A survival associations across molecular data types. TAF1A RNA expression shows survival associations in the most cancer types (29), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF1A RNA expression–survival associations across cancer types. High TAF1A expression shows unfavorable associations in CESC, KIRP, ACC, THCA and SARC, but favorable associations in UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for TAF1A RNA expression.
This table summarizes TAF1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TAF1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF1A shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, BLCA, LIHC and LUAD. The HNSC box plot shows higher TAF1A RNA expression in tumor versus normal tissue (log2 FC = +1.451, t-test p < 0.001).
This table shows molecular features associated with TAF1A in patient tissues and cancer cell lines. In patient samples, TAF1A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
